THE U.S. MONKEYPOX TESTING MARKET SIZE IS EXPECTED TO REACH USD 91 THOUSAND BY 2025.

The U.S. Monkeypox Testing Market Size, Share, & Trends Analysis Report By

  • Type: PCR, Lateral Flow Assay, and Others
  • End-User: Laboratories, Hospitals & Clinics, and Others
  • Geography: The U.S. (Southern, Western, Northeast, and Central)

Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2023–2025

Licence Types What are these?
GET ACTIONABLE INSIGHTS ON HOW COVID-19 IS IMPACTING YOUR BUSINESS
Enquire Now Download Free Sample

Most Exhaustive Report

icon-pages

165 Pages

icon-table

55 Tables

icon-chart

56 Charts

icon-region

4 Regions

icon-country

1 Countries

icon-company

36 Companies

icon-market

3 Market Segment

U.S. MONKEYPOX TESTING MARKET REPORT SCOPE

Report Attribute Details
Market Size (2025) USD 91.00 Thousand
Market Size (2022) USD 5,336.29 Thousand
CAGR (2022-2025) (74.26%)
Base Year 2022
Forecast Year 2023-2025
Market Segments Type, End-User, and Geography
REGIONAL ANALYSIS U.S. (Southern, Western, Northeast, and Central)
KEY VENDORS Abbott, F. Hoffmann-La Roche, Qiagen, and Thermo Fisher Scientific

The U.S. monkeypox testing market size was valued at USD 5,336.29 thousand in 2022 and is expected to reach USD 91 thousand by 2025. The market is projected to register a CAGR of (74.26%) during the forecast period. Monkeypox is an orthopoxviral related to the smallpox virus and initially affected the U.S. population in 2003. Cases of monkeypox increased at the beginning of 2022, and by the end of September, the U.S. became the country with a high number of monkeypox cases. Men accounted for the larger patient group in the country; however, the number of monkeypox cases among women and children was limited.

The major reason for the spread of the disease in the country was sex among men. The LGBT community was one of the majorly affected communities. The country has undergone a huge healthcare crisis due to COVID-19 cases and has taken significant steps to control the spread of infections in the market. The region increased the number of tests conducted and accessibility to the tests through various healthcare settings, thereby contributing to the U.S. monkeypox testing market. Such initiatives have helped the country manage the spread of the disease.

The COVID-19 pandemic made the U.S. healthcare system increase its testing capacity and handle outbreaks and pandemics better. The monkeypox virus was diagnosed through the PCR-based method, like the COVID-19 infection testing, and has helped the government immediately increase the testing and provide treatment to the infected people and contribute to the U.S. monkeypox testing market. From day one of this outbreak, providers had access to a high-quality, FDA-cleared test to detect monkeypox. The CDC has scaled the testing capacity to 78 sites in 48 states, primarily at state public health laboratories, with the capacity to conduct around 10,000 tests per week. In addition, CDC began shipping the tests to some of the largest commercial laboratory companies (including some of the nation’s largest reference laboratories) to increase monkeypox testing capacity. This action improved convenience for patients and healthcare providers across the nation, and the government eased the testing procedures by approving the rapid testing kits for monkeypox. The regulatory bodies approved the products faster and increased access to monkeypox testing, which further accelerated the U.S. monkeypox testing market. In addition, the government took better steps to create awareness, communicate among the LGBTQI+ community, mobilize them, and provide better treatments. It was estimated that the U.S. would require USD 7 billion to handle the monkeypox outbreak.

This expansion increased the testing accessibility, building on the capacities already available within the Laboratory Response Network (LRN). In addition, the CDC has worked with the LRN to increase public health testing capacity by more than 50% since the outbreak's start, increasing testing capacity from 6,000 tests per week to approximately 10,000 tests per week. This network continued to provide spare testing capacity to jurisdictions across the country. CDC worked with the state, territorial, and local health departments to make the monkeypox testing process more accessible to health care providers.

Monkeypox testing has become very significant in the high-risk community. Monkeypox lesions are extremely painful and curable, but the effect of monkeypox among undiagnosed HIV patients is extreme. This is increasing the number of tests conducted in the country. People with simpler symptoms also undergo monkeypox testing to protect them from other disease conditions. In addition, some factors have limited the Mpox testing. Factors like false positive results and the rollout of vaccines in the market reduced the spread of the infections. Such factors helped the government quickly monitor and reduce the country's monkeypox cases. However, this reduced the number of tests conducted in the market, which became a limitation for the U.S. monkeypox testing market.

Monkeypox Cases Are Down but Not Gone
Experts in infectious disease have made statements like monkeypox cases will never leave the country. The number of cases recorded in the U.S. was high but still considered an undercount. It is expected that more cases are not considered as the physicians have not seen this before. The virus will remain infectious for around three weeks. It is challenging for people to stay isolated for three weeks. There is a high chance that this infection will spread to the animal carriers like rodents and again jump back, reinfecting the human population. There are high chances of increasing the infection spread unless the vaccination process is complete. Developed Countries like the U.S. will largely invest in the testing infrastructure to reduce the spread of the disease in the country. Investment measures further support the growth of the U.S. monkeypox testing market. The “Panic buying” concept will hugely impact the industry, increasing the demand for Mpox testing.

Strong Future Diagnostic Pipeline
The U.S. has a strong pipeline in the monkeypox diagnostic segment. National Institutes of Health (NIH), National Institute of Biomedical Imaging and Bioengineering (NIBIB), Department of Defense (DOD), and more institutions have invested in advanced monkeypox diagnostics. The research results are to be released in the first half of 2023. The country is investing in the future-ready diagnostics segment, which will help the region defend against future cases.

MARKET TRENDS & OPPORTUNITIES

Ongoing U.S. Monkeypox Research Activities
Government departments and agencies, with international allies and partners, are accelerating efforts to undertake critical monkeypox research questions to inform the outbreak response and strategically planning to launch further research. Insights from this research will guide swift action during a public health emergency. These studies are poised to yield insights that will accelerate efforts to combat monkeypox, but more research is needed to fill the priority gaps. The Monkeypox Research Priority Team, led by the White House Office of Science and Technology Policy (OSTP) and including experts across the US government, is developing science and research programs to accelerate the monkeypox outbreak response in the country. Such factors are anticipated to support the U.S. monkeypox testing market growth.

Rapidly Growing Commercial Laboratory-Developed Monkeypox Testing
On 22 June 2022, the U.S. Department of Health and Human Services (HHS) announced the authorization of commercial laboratories to conduct monkeypox tests to expand testing as the U.S. confronts a monkeypox outbreak dramatically, thereby propelling the U.S. monkeypox testing market. The Centers for Disease Control and Prevention (CDC) shipped test kits to commercial laboratory companies, allowing health providers to order tests from the labs directly. These commercial laboratories dramatically expanded testing capacity nationwide and made testing more convenient and accessible for patients and healthcare providers. In addition to the FDA-approved or EUA-approved monkeypox tests (MPOX), certain laboratory-developed tests (LDTs) are also being used to detect monkeypox that has not been reviewed or approved by the FDA. LDT is a type of in vitro diagnostic test designed, manufactured, and used in a CLIA-accredited laboratory at a single site that meets the requirements of a highly complex test.

REGIONAL ANALYSIS

The Southern region accounted for the largest U.S. monkeypox testing market share at 33.58%. The perception that the response to the monkeypox virus in the South has lacked coordination has rekindled familiar concerns about recent state policies. States like California have followed the CDC's recommendation to prioritize gay and bisexual men in outreach, vaccination, and treatment for monkeypox. Such states have declared a public health emergency and initiated aggressive, targeted vaccination campaigns. Although California has the highest number of cases, Florida, Georgia, and Texas are home to robust gay communities and have just over a quarter of the country’s confirmed monkeypox cases.

COMPETITIVE LANDSCAPE

Amid the CDC’s orthopoxvirus test expansion, several diagnostics companies are developing and launching their monkeypox-specific assays. BD, Cepheid, and Roche have joined the race to roll out accurate, PCR-quality tests for the disease. BD has joined forces with CerTest to adapt one of the Spanish company’s existing tests to run on the BD Max automated PCR system. At the same time, Cepheid partnered with reagent maker BioGX to design a molecular assay of its own. Abbott is developing a polymerase chain reaction (PCR) test to detect the presence of monkeypox. The company is focused on developing a monkeypox test, which could help the world in the early detection of the disease. It will provide test kits to partners in the pandemic defense coalition. In addition, F. Hoffman La Roche launches LightMix Modular Virus test kits to analyze samples using quantitative PCR technology. Various companies across the globe are developing monkeypox test kits to increase the testing and to decrease the spread of infection globally.

Frequently Asked Questions

How big is the U.S. monkeypox testing market?

The U.S. monkeypox testing market was valued at USD 5,336.29 thousand in 2022 and is expected to reach USD 91 thousand by 2025.

What is the projected CAGR of the U.S. monkeypox testing market during the forecast period?

The U.S. monkeypox testing market is expected to decline at a CAGR of (74.26%) during the forecast period.

Which are the key players in the U.S. monkeypox testing market?

Abbott, F. Hoffmann-La Roche, Qiagen, and Thermo Fisher Scientific are the key companies in the U.S. monkeypox testing market.

Which region holds the largest U.S. monkeypox testing market share?

The southern region dominates the U.S. monkeypox testing market, with a share of 33.58% in 2022.

What are the growing trends in the U.S. monkeypox testing market?

The growing trends in the U.S. monkeypox testing market are ongoing research activities, the rapid development of rapid testing methods, and rapidly growing commercial laboratory-developed monkeypox testing.

Download Free Sample

The U.S. monkeypox testing market was valued at USD 5,336.29 thousand in 2022 and is expected to reach USD 91.00 thousand by 2025.

The following factors are likely to contribute to the growth of the U.S. monkeypox testing market during the forecast period:

  • Increasing Product Launches
  • Advancements in PCR Technology
  • Monkeypox Eradication is Unlikely to Continue in the U.S.

Base Year: 2022

Forecast Year: 2023-2025

The report considers the present scenario of the U.S. monkeypox testing market and its market dynamics for 2023−2025. It covers a detailed overview of several market growth enablers, restraints, and trends. The study covers both the demand and supply sides of the industry. It also profiles and analyzes leading companies and several other prominent companies operating in the industry.

Key Company Profiles

  • Abbott
    • Business Overview
    • Product Offerings
    • Key Strategies
    • Key Strengths
    • Key Opportunities
  • F. Hoffmann-La Roche
  • Qiagen
  • Thermo Fisher Scientific

Other Prominent Vendors

  • Alpha Diagnostic
    • Business Overview
    • Product Offerings
  • AtliaBiosystems
  • Applied DNA Sciences
  • BioGX
  • BIONEER
  • CERTEST BIOTEC
  • Co-Diagnostics
  • CorDx
  • Creative Biogene
  • Elabscience Biotechnology
  • LABNOVATION TECHNOLOGIES
  • Seegene

Laboratory-Developed Monkeypox Tests

  • Aegis Sciences
    • Business Overview
    • Product Offerings
  • ARUP Laboratories
  • Apostle Diagnostics
  • California Department of Public Health
  • CDR Companies
  • CirrusDx
  • Clinical Reference Laboratory
  • Devlab Bio
  • Discover Labs
  • Integrity Laboratories
  • Laboratory Corporation of America Holdings
  • Madison Core Laboratories
  • Mako Medical Laboratories
  • Mayo Clinic
  • Quest Diagnostics
  • RapidBio
  • Shepard Health
  • Sonic Healthcare
  • US BioTek Laboratories
  • UW Virology Laboratory

Segmentation By Type

  • PCR
  • Lateral Flow Assay
  • Others

Segmentation By End-User

  • Laboratories
  • Hospitals & Clinics
  • Others

Segmentation By Region

  • U.S.
    • Southern
    • Western
    • Northeast
    • Central

1 RESEARCH METHODOLOGY

2 RESEARCH OBJECTIVES

3 RESEARCH PROCESS

4 SCOPE & COVERAGE

4.1 MARKET DEFINITION

4.1.1 INCLUSIONS

4.1.2 EXCLUSIONS

4.1.3 MARKET ESTIMATION CAVEATS

4.2 BASE YEAR

4.3 SCOPE OF THE STUDY

4.3.1 MARKET SEGMENTATION BY TYPE

4.3.2 MARKET SEGMENTATION BY END-USER

4.3.3 MARKET SEGMENTATION BY REGION

5 REPORT ASSUMPTIONS & CAVEATS

5.1 KEY CAVEATS

5.2 CURRENCY CONVERSION

5.3 MARKET DERIVATION

6 PREMIUM INSIGHTS

6.1 OVERVIEW

7 MARKET AT A GLANCE

8 INTRODUCTION

8.1 OVERVIEW

9 MARKET OPPORTUNITIES & TRENDS

9.1 ONGOING US MONKEYPOX RESEARCH ACTIVITIES

9.2 GROWING DEVELOPMENT OF RAPID TESTING METHODS

9.3 RAPIDLY GROWING COMMERCIAL LABORATORY-DEVELOPED MONKEYPOX TESTING

10 MARKET GROWTH ENABLERS

10.1 INCREASING PRODUCT LAUNCHES

10.2 ADVANCES IN PCR TECHNOLOGY

10.3 MONKEYPOX ERADICATION UNLIKELY TO CONTINUE IN US

11 MARKET RESTRAINTS

11.1 GROWING ACCESS TO VACCINATION AGAINST MONKEYPOX

11.2 MONKEYPOX CASES ARE IN A SHARP DECLINE

11.3 POTENTIAL RISK OF FALSE MONKEYPOX TEST RESULTS

12 MARKET LANDSCAPE

12.1 MARKET OVERVIEW

12.1.1 INSIGHTS BY TYPE

12.1.2 INSIGHTS BY END-USER

12.1.3 INSIGHTS BY REGION

12.2 FIVE FORCES ANALYSIS

12.2.1 THREAT OF NEW ENTRANTS

12.2.2 BARGAINING POWER OF SUPPLIERS

12.2.3 BARGAINING POWER OF BUYERS

12.2.4 THREAT OF SUBSTITUTES

12.2.5 COMPETITIVE RIVALRY

13 TESTING TYPE

13.1 MARKET SNAPSHOT & GROWTH ENGINE

13.2 MARKET OVERVIEW

13.3 POLYMERASE CHAIN REACTION (PCR)

13.3.1 MARKET OVERVIEW

13.3.2 MARKET SIZE & FORECAST

13.4 LATERAL FLOW ASSAY

13.4.1 MARKET OVERVIEW

13.4.2 MARKET SIZE & FORECAST

13.5 OTHER

13.5.1 MARKET OVERVIEW

13.5.2 MARKET SIZE & FORECAST

14 END-USER

14.1 MARKET SNAPSHOT & GROWTH ENGINE

14.2 MARKET OVERVIEW

14.3 LABORATORIES

14.3.1 MARKET OVERVIEW

14.3.2 MARKET SIZE & FORECAST

14.4 HOSPITALS & CLINICS

14.4.1 MARKET OVERVIEW

14.4.2 MARKET SIZE & FORECAST

14.5 OTHERS

14.5.1 MARKET OVERVIEW

14.5.2 MARKET SIZE & FORECAST

15 REGION

15.1 MARKET SNAPSHOT & GROWTH ENGINE

15.2 MARKET OVERVIEW

15.3 SOUTHERN

15.3.1 MARKET OVERVIEW

15.3.2 MARKET SIZE & FORECAST

15.4 WESTERN

15.4.1 MARKET OVERVIEW

15.4.2 MARKET SIZE & FORECAST

15.5 NORTHEAST

15.5.1 MARKET OVERVIEW

15.5.2 MARKET SIZE & FORECAST

15.6 CENTRAL

15.6.1 MARKET OVERVIEW

15.6.2 MARKET SIZE & FORECAST

16 COMPETITIVE LANDSCAPE

16.1 COMPETITION OVERVIEW

16.2 MARKET SHARE ANALYSIS

16.2.1 ABBOTT

16.2.2 F. HOFFMANN-LA ROCHE

16.2.3 QIAGEN

16.2.4 THERMO FISHER SCIENTIFIC

17 KEY COMPANY PROFILES

17.1 ABBOTT

17.1.1 BUSINESS OVERVIEW

17.1.2 PRODUCT OFFERINGS

17.1.3 KEY STRATEGIES

17.1.4 KEY STRENGTHS

17.1.5 KEY OPPORTUNITIES

17.2 F. HOFFMANN-LA ROCHE

17.2.1 BUSINESS OVERVIEW

17.2.2 PRODUCT OFFERINGS

17.2.3 KEY STRATEGIES

17.2.4 KEY STRENGTHS

17.2.5 KEY OPPORTUNITIES

17.3 QIAGEN

17.3.1 BUSINESS OVERVIEW

17.3.2 PRODUCT OFFERINGS

17.3.3 KEY STRATEGIES

17.3.4 KEY STRENGTHS

17.3.5 KEY OPPORTUNITIES

17.4 THERMO FISHER SCIENTIFIC

17.4.1 BUSINESS OVERVIEW

17.4.2 PRODUCT OFFERINGS

17.4.3 KEY STRATEGIES

17.4.4 KEY STRENGTHS

17.4.5 KEY OPPORTUNITIES

18 OTHER PROMINENT VENDORS

18.1 ALPHA DIAGNOSTIC

18.1.1 BUSINESS OVERVIEW

18.1.2 PRODUCT OFFERINGS

18.2 ATILABIOSYSTEMS

18.2.1 BUSINESS OVERVIEW

18.2.2 PRODUCT OFFERINGS

18.3 APPLIED DNA SCIENCES

18.3.1 BUSINESS OVERVIEW

18.3.2 PRODUCT OFFERINGS

18.4 BIOGX

18.4.1 BUSINESS OVERVIEW

18.4.2 PRODUCT OFFERINGS

18.5 BIONEER

18.5.1 BUSINESS OVERVIEW

18.5.2 PRODUCT OFFERINGS

18.6 CERTEST BIOTEC

18.6.1 BUSINESS OVERVIEW

18.6.2 PRODUCT OFFERINGS

18.7 CO-DIAGNOSTICS

18.7.1 BUSINESS OVERVIEW

18.7.2 PRODUCT OFFERINGS

18.8 CORDX

18.8.1 BUSINESS OVERVIEW

18.8.2 PRODUCT OFFERINGS

18.9 CREATIVE BIOGENE

18.9.1 BUSINESS OVERVIEW

18.9.2 PRODUCT OFFERINGS

18.10 ELABSCIENCE BIOTECHNOLOGY

18.10.1 BUSINESS OVERVIEW

18.10.2 PRODUCT OFFERINGS

18.11 LABNOVATION TECHNOLOGIES

18.11.1 BUSINESS OVERVIEW

18.11.2 PRODUCT OFFERINGS

18.12 SEEGENE

18.12.1 BUSINESS OVERVIEW

18.12.2 PRODUCT OFFERINGS

19 LABORATORY-DEVELOPED MONKEYPOX TESTS

19.1 AEGIS SCIENCES

19.1.1 BUSINESS OVERVIEW

19.1.2 PRODUCT OFFERINGS

19.2 ARUP LABORATORIES

19.2.1 BUSINESS OVERVIEW

19.2.2 PRODUCT OFFERINGS

19.3 APOSTLE DIAGNOSTICS

19.3.1 BUSINESS OVERVIEW

19.3.2 PRODUCT OFFERINGS

19.4 CALIFORNIA DEPARTMENT OF PUBLIC HEALTH

19.4.1 BUSINESS OVERVIEW

19.4.2 PRODUCT OFFERINGS

19.5 CDR COMPANIES

19.5.1 BUSINESS OVERVIEW

19.5.2 PRODUCT OFFERINGS

19.6 CIRRUSDX

19.6.1 BUSINESS OVERVIEW

19.6.2 PRODUCT OFFERINGS

19.7 CLINICAL REFERENCE LABORATORY

19.7.1 BUSINESS OVERVIEW

19.7.2 PRODUCT OFFERINGS

19.8 DEVLAB BIO

19.8.1 BUSINESS OVERVIEW

19.8.2 PRODUCT OFFERINGS

19.9 DISCOVER LABS

19.9.1 BUSINESS OVERVIEW

19.9.2 PRODUCT OFFERINGS

19.10 INTEGRITY LABORATORIES

19.10.1 BUSINESS OVERVIEW

19.10.2 PRODUCT OFFERINGS

19.11 LABORATORY CORPORATION OF AMERICA HOLDINGS

19.11.1 BUSINESS OVERVIEW

19.11.2 PRODUCT OFFERINGS

19.12 MADISON CORE LABORATORIES

19.12.1 BUSINESS OVERVIEW

19.12.2 PRODUCT OFFERINGS

19.13 MAKO MEDICAL LABORATORIES

19.13.1 BUSINESS OVERVIEW

19.13.2 PRODUCT OFFERINGS

19.14 MAYO CLINIC

19.14.1 BUSINESS OVERVIEW

19.14.2 PRODUCT OFFERINGS

19.15 QUEST DIAGNOSTICS

19.15.1 BUSINESS OVERVIEW

19.15.2 PRODUCT OFFERINGS

19.16 RAPIDBIO

19.16.1 BUSINESS OVERVIEW

19.16.2 PRODUCT OFFERINGS

19.17 SHEPARD HEALTH

19.17.1 BUSINESS OVERVIEW

19.17.2 PRODUCT OFFERINGS

19.18 SONIC HEALTHCARE

19.18.1 BUSINESS OVERVIEW

19.18.2 PRODUCT OFFERINGS

19.19 US BIOTEK LABORATORIES

19.19.1 BUSINESS OVERVIEW

19.19.2 PRODUCT OFFERINGS

19.2 UW VIROLOGY LABORATORY

19.20.1 BUSINESS OVERVIEW

19.20.2 PRODUCT OFFERINGS

20 REPORT SUMMARY

20.1 KEY TAKEAWAYS

20.2 STRATEGIC RECOMMENDATIONS

21 QUANTITATIVE SUMMARY

21.1 MARKET BY TYPE

21.2 MARKET BY END-USER

21.3 MARKET BY REGION

22 APPENDIX

22.1 ABBREVIATIONS

LIST OF EXHIBITS

EXHIBIT 1 SEGMENTATION OF US MONKEYPOX TESTING MARKET

EXHIBIT 2 MARKET SIZE CALCULATION APPROACH 2022

EXHIBIT 3 OVERVIEW OF US MONKEYPOX TESTING MARKET (2022-2025)

EXHIBIT 4 OVERVIEW OF MONKEYPOX DIAGNOSTICS WITHIN TIME FRAMES

EXHIBIT 5 IMPACT OF ONGOING US MONKEYPOX RESEARCH ACTIVITIES

EXHIBIT 6 IMPACT OF GROWING DEVELOPMENT OF RAPID TESTING METHODS

EXHIBIT 7 IMPACT OF RAPIDLY GROWING COMMERCIAL LABORATORY-DEVELOPED MONKEYPOX TESTING

EXHIBIT 8 IMPACT OF INCREASING PRODUCT LAUNCHES

EXHIBIT 9 IMPACT OF ADVANCES IN PCR TECHNOLOGY

EXHIBIT 10 IMPACT OF MONKEYPOX ERADICATION UNLIKELY TO CONTINUE IN US

EXHIBIT 11 IMPACT OF GROWING ACCESS TO VACCINATION AGAINST MONKEYPOX

EXHIBIT 12 IMPACT OF MONKEYPOX CASES IN A SHARP DECLINE

EXHIBIT 13 US MONKEYPOX CASES

EXHIBIT 14 IMPACT OF POTENTIAL RISK OF FALSE MONKEYPOX TEST RESULTS

EXHIBIT 15 US MONKEYPOX TESTING MARKET 2022–2025 ($ THOUSAND)

EXHIBIT 16 US MONKEYPOX TESTING MARKET BY TYPE 2022-2025 (%)

EXHIBIT 17 US MONKEYPOX TESTING MARKET BY END-USER 2022-2025 (%)

EXHIBIT 18 US MONKEYPOX TESTING MARKET BY REGION 2022-2025 (%)

EXHIBIT 19 FIVE FORCES ANALYSIS 2022

EXHIBIT 20 INCREMENTAL GROWTH BY TYPE 2022 & 2025

EXHIBIT 21 US MONKEYPOX TESTING MARKET BY TYPE: INCREMENTAL GROWTH ($ THOUSAND)

EXHIBIT 22 US MONKEYPOX TESTING MARKET BY TYPE: ABSOLUTE GROWTH (%)

EXHIBIT 23 US PCR MONKEYPOX TESTING MARKET: INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 24 US PCR MONKEYPOX TESTING MARKET 2022–2025 ($ THOUSAND)

EXHIBIT 25 US LATERAL FLOW ASSAY MONKEYPOX TESTING MARKET: INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 26 US LATERAL FLOW ASSAY MONKEYPOX TESTING MARKET 2022–2025 ($ THOUSAND)

EXHIBIT 27 US OTHER MONKEYPOX TESTING MARKET: INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 28 US OTHER MONKEYPOX TESTING MARKET 2022–2025 ($ THOUSAND)

EXHIBIT 29 INCREMENTAL GROWTH BY END-USER 2022 & 2025

EXHIBIT 30 US MONKEYPOX TESTING MARKET BY END-USER: INCREMENTAL GROWTH ($ THOUSAND)

EXHIBIT 31 US MONKEYPOX TESTING MARKET BY END-USER: ABSOLUTE GROWTH (%)

EXHIBIT 32 US LABORATORIES MONKEYPOX TESTING MARKET: INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 33 US LABORATORIES MONKEYPOX TESTING MARKET 2022–2025 ($ THOUSAND)

EXHIBIT 34 US HOSPITALS & CLINICS MONKEYPOX TESTING MARKET: INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 35 US HOSPITALS & CLINICS MONKEYPOX TESTING MARKET 2022–2025 ($ THOUSAND)

EXHIBIT 36 US INDIVIDUALS MONKEYPOX TESTING MARKET: INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 37 US OTHER MONKEYPOX TESTING MARKET 2022–2025 ($ THOUSAND)

EXHIBIT 38 INCREMENTAL GROWTH BY REGION 2022 & 2025

EXHIBIT 39 US MONKEYPOX TESTING MARKET BY REGION: INCREMENTAL GROWTH ($ THOUSAND)

EXHIBIT 40 US MONKEYPOX TESTING MARKET BY REGION: ABSOLUTE GROWTH (%)

EXHIBIT 41 SOUTHERN US MONKEYPOX TESTING MARKET: INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 42 SOUTHERN US MONKEYPOX TESTING MARKET 2022–2025 ($ THOUSAND)

EXHIBIT 43 WESTERN US MONKEYPOX TESTING MARKET: INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 44 WESTERN US MONKEYPOX TESTING MARKET 2022–2025 ($ THOUSAND)

EXHIBIT 45 NORTHEAST US MONKEYPOX TESTING MARKET: INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 46 NORTHEAST US MONKEYPOX TESTING MARKET 2022–2025 ($ THOUSAND)

EXHIBIT 47 CENTRAL US MONKEYPOX TESTING MARKET: INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 48 CENTRAL US MONKEYPOX TESTING MARKET 2022–2025 ($ THOUSAND)

EXHIBIT 49 US VENDORS OFFERING COMMERCIAL MONKEYPOX TESTING: MARKET DOMINANCE ANALYSIS

EXHIBIT 50 US MONKEYPOX TESTING MARKET: VENDORS OFFERING COMMERCIAL MONKEYPOX TESTING - CAPABILITIES & EXPERTISE ASSESSMENT

EXHIBIT 51 F. HOFFMANN-LA ROCHE : TOTAL REVENUE 2019−2021 ($ BILLION)

EXHIBIT 52 F. HOFFMANN-LA ROCHE: R&D EXPENDITURE 2019−2021 ($ BILLION)

EXHIBIT 53 THERMO FISHER SCIENTIFIC: TOTAL REVENUE 2019-2021 ($ MILLIONS)

EXHIBIT 54 THERMO FISHER SCIENTIFIC: R&D EXPENDITURE 2020-2021 ($ MILLIONS)

EXHIBIT 55 THERMO FISHER SCIENTIFIC: REVENUE BY BUSINESS SEGMENT 2020-2021 ($ MILLIONS)

EXHIBIT 56 THERMO FISHER SCIENTIFIC: REVENUE BY GEOGRAPHY 2021 ($ MILLIONS)

TABLE 1 KEY CAVEATS

TABLE 2 CURRENCY CONVERSION 2015−2022

TABLE 3 MOLECULAR METHODS FOR NUCLEIC ACID DETECTION

TABLE 4 IMMUNOLOGICAL METHODS FOR ANTIBODY OR ANTIGEN DETECTION

TABLE 5 US MONKEYPOX RESEARCH PRIORITIES

TABLE 6 US MONKEYPOX RESEARCH SUMMARY

TABLE 7 FDA-APPROVED PCR TESTS FOR MONKEYPOX

TABLE 8 COMPANIES OFFERING LATERAL FLOW ASSAY FOR MONKEYPOX TESTING

TABLE 9 US LIST OF LABORATORIES OFFERING NOTIFIED LABORATORY-DEVELOPED MONKEYPOX TESTS

TABLE 10 SOUTHERN US CASE COUNT (2023)

TABLE 11 WESTERN US MONKEYPOX CASE COUNT (2023)

TABLE 12 NORTHEAST US MONKEYPOX CASES COUNT (2023)

TABLE 13 CENTRAL US MONKEYPOX CASES COUNT (2023)

TABLE 14 ABBOTT: MAJOR PRODUCT OFFERINGS

TABLE 15 F. HOFFMANN-LA ROCHE: MAJOR PRODUCT OFFERINGS

TABLE 16 QIAGEN: MAJOR PRODUCT OFFERINGS

TABLE 17 THERMO FISHER SCIENTIFIC: MAJOR PRODUCT OFFERINGS

TABLE 18 ALPHA DIAGNOSTIC: MAJOR PRODUCT OFFERINGS

TABLE 19 ATLIABIOSYSTEMS: MAJOR PRODUCT OFFERINGS

TABLE 20 APPLIED DNA SCIENCES: MAJOR PRODUCT OFFERINGS

TABLE 21 BIOGX: MAJOR PRODUCT OFFERINGS

TABLE 22 BIONEER: MAJOR PRODUCT OFFERINGS

TABLE 23 CERTEST BIOTEC: MAJOR PRODUCT OFFERINGS

TABLE 24 CO-DIAGNOSTICS: MAJOR PRODUCT OFFERINGS

TABLE 25 CORDX: MAJOR PRODUCT OFFERINGS

TABLE 26 CREATIVE BIOGENE: MAJOR PRODUCT OFFERINGS

TABLE 27 ELABSCIENCE BIOTECHNOLOGY: MAJOR PRODUCT OFFERINGS

TABLE 28 LABNOVATION TECHNOLOGIES: MAJOR PRODUCT OFFERINGS

TABLE 29 SEEGENE: MAJOR PRODUCT OFFERINGS

TABLE 30 AEGIS SCIENCES: MAJOR PRODUCT OFFERINGS

TABLE 31 ARUP LABORATORIES: MAJOR PRODUCT OFFERINGS

TABLE 32 APOSTLE DIAGNOSTICS: MAJOR PRODUCT OFFERINGS

TABLE 33 CALIFORNIA DEPARTMENT OF PUBLIC HEALTH: MAJOR PRODUCT OFFERINGS

TABLE 34 CDR COMPANIES: MAJOR PRODUCT OFFERINGS

TABLE 35 CIRRUSDX: MAJOR PRODUCT OFFERINGS

TABLE 36 CLINICAL REFERENCE LABORATORY: MAJOR PRODUCT OFFERINGS

TABLE 37 DEVLAB BIO: MAJOR PRODUCT OFFERINGS

TABLE 38 DISCOVER LABS: MAJOR PRODUCT OFFERINGS

TABLE 39 INTEGRITY LABORATORIES: MAJOR PRODUCT OFFERINGS

TABLE 40 LABORATORY CORPORATION OF AMERICA HOLDINGS: MAJOR PRODUCT OFFERINGS

TABLE 41 MADISON CORE LABORATORIES: MAJOR PRODUCT OFFERINGS

TABLE 42 MAKO MEDICAL LABORATORIES: MAJOR PRODUCT OFFERINGS

TABLE 43 MAYO CLINIC: MAJOR PRODUCT OFFERINGS

TABLE 44 QUEST DIAGNOSTICS: MAJOR PRODUCT OFFERINGS

TABLE 45 RAPIDBIO: MAJOR PRODUCT OFFERINGS

TABLE 46 SHEPARD HEALTH: MAJOR PRODUCT OFFERINGS

TABLE 47 SONIC HEALTHCARE: MAJOR PRODUCT OFFERINGS

TABLE 48 US BIOTEK LABORATORIES: MAJOR PRODUCT OFFERINGS

TABLE 49 UW VIROLOGY LABORATORY: MAJOR PRODUCT OFFERINGS

TABLE 50 US MONKEYPOX TESTING MARKET BY TYPE 2022−2025 ($ THOUSAND)

TABLE 51 US MONKEYPOX TESTING MARKET BY TYPE 2022−2025 (%)

TABLE 52 US MONKEYPOX TESTING MARKET BY END-USER 2022−2025 ($ THOUSAND)

TABLE 53 US MONKEYPOX TESTING MARKET BY END-USER 2022−2025 (%)

TABLE 54 US MONKEYPOX TESTING MARKET BY REGION 2022−2025 ($ THOUSAND)

TABLE 55 US MONKEYPOX TESTING MARKET BY REGION 2022−2025 (%)

 

Select a license type that suits your business needs

single-user Single User Licence
$3500.00
  • Report accessible by one user only
  • Free 10% or 3 days of customization
  • Free post-sale service assistance
  • Continuous support through email
Best Value Tag
5-user 5 User Licence
$3995.00
  • Report accessible by 5 users within the organization
  • Free 15% or 4.5 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
corporate.png Corporate Licence
$4995.00
  • Free Datasheet worth $1500
  • Report accessible by the entire organization
  • Free 20% or 6 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Direct access to lead analysts
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
datasheet.png Datasheet Licence
$2000.00
  • Report accessible by 1 user only
  • Free 15% or 32 hours of customization
  • Free post-sale service assistance
  • Direct access to lead analysts

Our Clients

Licence Types What are these?

Interested in data center portfolio for this report?
Click here

Our Clients Speak

erick

"The report by Arizton was spot on. It not only gave us insight into the pro audio market, we used it to raise funds for our company. The data proved (to the VC we pitched to) that the market was large enough for our company to not only survive but also grow."

Erik Young
CEO, Co-founder
Audink Inc., DBA Audios
SPEAK WITH OUR ANALYST

Want to know more about the report or any specific requirement?

Click to Email +1-312-235-2040

Want to Customize the Report?

Click Here

Why Arizton?

  • 100% Customer Satisfaction
  • 24x7 availability – we are always there when you need us
  • 200+ Fortune 500 Companies trust Arizton's report
  • 80% of our reports are exclusive and first in the industry
  • 100% more data and analysis
  • 1000+ reports published till date